This review attempts to portray the discovery and development of anticancer agents/drugs from diverse natural sources. Natural molecules from these natural sources including plants, microbes and marine organisms have been the basis of treatment of human diseases since the ancient times. Compounds derived from nature have been important sources of new drugs and also serve as templates for synthetic modification. Many successful anti-cancer drugs currently in use are naturally derived or their analogues and many more are under clinical trials. This review aims to highlight the invaluable role that natural products have played, and continue to play, in the discovery of anticancer agents.
ShahU., ShahR., AcharyaS., AcharyaN. (2013) Novel anticancer agents from plant sources. Chinese Journal of Natural Medicines, 11, 0016–0023.
2.
CraggG.M., NewmanD.J. (2005) Plants as a source of anti-cancer agents. Journal of Ethnopharmacology, 100, 72–79.
3.
KhazirJ., MirB.A., MirS.A., DonC. (2013) Natural products as lead compounds in drug discovery. Journal of Asian Natural Products Research, 15, 764–788.
4.
NewmanD.J., CraggG.M. (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal of Natural Products, 75, 311–335.
5.
NewmanD.J., CraggG.M. (2007) Natural products as sources of new drugs over the last 25 years. Journal of Natural Products, 70, 1022–1037.
6.
JoanneB., MuraliD., WilliamE., NilsL. (2011) To Market To Market, Annual Reports in Medicinal Chemistry, Chapter 26, Volume 46, Pages 433–602.
7.
CraggG.M., KingstonD.J., NewmanD.J. (2012) Anticancer agents from natural products, Second Edition CRC Press, Pages 1–577.
8.
PeterE., SilvioR., AnsgarS. (2008) Natural product-likeness score and its application for prioritization of compound libraries. Journal of Chemical Information and Modeling, 48, 68–74.
9.
SusanL.H., JerryM.C., JamesH.D. (2010) Analysis of FDA-approved anti-Cancer agents in the NCI60 panel of human tumor cell lines. Molecular Cancer Therapeutics, 9, 1451–1460.
10.
AnandC., NeetuS. (2011) Contribution of world health organization in the global acceptance of Ayurveda. Journal of Ayurveda Integrative Medicine, 2, 179–186.
11.
KhazirJ., MirB.A., PilcherL., RileyD.L. (2014) Role of plants in anticancer drug discovery. Phytochemistry letters, 7, 173–181.
GelmonK.A. (1994) The Taxoids: paclitaxel and docetaxel. Lancet, 344, 1267–1272.
17.
ChanningJ.P., EmmanuelS.A. (2011) Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design Development Therapy, 5, 117–124.
PayneM., EllisP., DunlopD., RansonM., DansonS., SchacterL., TalbotD. (2006) DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. Journal of Thoracic Oncology, 1, 984–990.
RobertF., HarperK., AckermanJ., GuptaS. (2010) A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemotherapy Pharmacology, 65, 227–234.
22.
DiérasV., LimentaniS., RomieuG., Tubiana-HulinM., LortholaryA., KaufmanP., GirreV., BesenvalM., ValeroV. (2008) Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Annals of Oncology, 19, 1255–60.
RamanathanR.K., PicusJ., RaftopoulosH., BernardS., LockhartA.C., FrenetteG., MacdonaldJ., MelinS., BergD., BresciaF., HochsterH., CohnA. (2008) A phase II study of Milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemotherapy Pharmacology, 61, 453–458.
25.
FitzgeraldD.P., EmersonD.L., QianY., AnwarT., LiewehrD.J., SteinbergS.M., SilbermanS., PalmieriD., SteegP.S. (2012) TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Molecular Cancer Therapeutics, 11, 1959–1967.
HeathE.I., LorussoP., RamalingamS.S., AwadaA., EgorinM.J., Besse-HamerT., CardosoF., ValdiviesoM., HasT., AllandL., ZhouX., BelaniC.P. (2011) A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Investigational New Drugs, 29, 1426–1431.
28.
SaifM.W., SarantopoulosJ., PatnaikA., TolcherA.W., TakimotoC., BeeramM. (2011) Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 68, 1565–1573.
ScottL., SoepenbergO., VerweijJ., de JongeM.J., Th PlantingA.S., McGovernD., PrincipeP., ObachR., TwelvesC. (2007) A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Annals of Oncology, 18, 569–575.
ZhuA.X., ReadyN., ClarkJ.W., SafranH., AmatoA., SalemN., PaceS., HeX., ZverevaN., LynchT.J., RyanD.P., SupkoJ.G. (2009) Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clinical Cancer Research, 15, 374–81.
33.
PecorelliS., Ray-CoquardI., TredanO., ColomboN., ParmaG., TisiG., KatsaròsD, LhomméC., LissoniA.A., VermorkenJ.B., BoisA Du, PovedaA., FrigerioL, BarbieriP., CarminatiP., BrienzaS., GuastallaJ.P. (2010) Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Annals of Oncology, 21, 759–765.
34.
AdilD., NikolaV., BarbaraC., JenniferD., PatriciaS., PamelaM., PatriciaU., RonaldC.D., ElmerB., ZhenmeiL., FrederickH., DanielS. (2005) Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study. Clinical Cancer Research, 11, 3009–3016.
FarrayD., AhluwaliaM.S., SnyderJ., BarnettG.H., CohenB.H., SuhJ.H., PeereboomD.M. (2006) Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme. Investigational New Drugs, 24, 177–180.
37.
TrocónizI.F., CendrósJ.M., SotoE., PruñonosaJ., Perez-MayoralA., PeraireC., PrincipeP., DelavaultP., CvitkovicF., LesimpleT., ObachR. (2012) Population pharmacokinetic /pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, Elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer Chemotherapy Pharmacology, 70, 239–250.
38.
AjaniJ.A., TakimotoC., BecerraC.R., SilvaA., BaezL., CohnA., MajorP., KamidaM., FeitK., De JagerR. (2005) A phase II clinical and pharmacokinetic study of intravenous Exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Investigational New Drugs, 23, 479–484.
MrossK., HüttmannA., HerbstK., HanauskeA.R., SchillingT., ManegoldC., BurkK., HossfeldD.K. (1996) Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Cancer Chemotherapy Pharmacology, 38, 217–224.
42.
SargentJ.M., ElgieA.W., WilliamsonC.J., HillB.T. (2003) Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs, 14, 467–473.
43.
ZhangY., TrisselL.A. (1999) Physical and chemical stability of etoposide phosphate solutionsJournal of American Pharmaceutical Association (Wash), 39, 146–150.
44.
NathanP., ZweifelM., PadhaniA.R., KohD.M., NgM., CollinsD.J., HarrisA., CardenC., SmytheJ., FisherN., TaylorN.J., StirlingJ.J., LuS.P., LeachM.O., RustinG.J., JudsonI. (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clinical Cancer Research, 18, 3428–3439.
45.
PattersonD.M., ZweifelM., MiddletonM.R., PriceP.M., FolkesL.K., StratfordM.R., RossP., HalfordS., PetersJ., BalkissoonJ., ChaplinD.J., PadhaniA.R., RustinG.J. (2012) Phase I Clinical and Pharmacokinetic Evaluation of the Vascular Disrupting Agent OXi4503 in Patients with Advanced Solid. Clinical Cancer Research, 18, 1415–25.
46.
MullauerF.B., KesslerJ.H., MedemaJ.P. (2010) Betulinic acid, a natural compound with potent anticancer effects. Anti-cancer Drugs, 21, 215–227.
47.
SudhakarC., SabithaP., PingL., SatyaP., StephenS. (2011) Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasomedependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer, 11, 371–382.
48.
ShailendraK. (2012) Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia. Journal of Zhejiang University Science B, 13, 761–762.
49.
BlancoE., BeyE.A., KhemtongC., YangS.G., Setti-GuthiJ., ChenH., KessingerC.W., CarnevaleK.A., BornmannW.G., BoothmanD.A., GaoJ. (2010) Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Research, 70, 3896–3904.
ShehzadA., WahidF., LeeY.S. (2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm (Weinheim), 343, 489–499.
54.
BhattacharyyaB., PandaD., GuptaS., BanerjeeM. (2008) Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Medicinal Research Reviews, 28, 155–183.
55.
JungY.L., HeeS.K., Yong-SangS. (2012) Genistein as a Potential Anticancer Agent against Ovarian Cancer. Journal of Traditional Complement Medicine, 2, 96–104.
56.
MessingE., GeeJ.R., SaltzsteinD.R., KimK., diSant'AgneseA., KolesarJ., HarrisL., FaerberA., HavighurstT., YoungJ.M., EfrosM., GetzenbergR.H., WheelerM.A., TangreaJ., ParnesH., HouseM., BusbyJ.E., HohlR., BaileyH. (2012) A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Preview Research (Phila), 5, 621–630.
57.
LevisS., Strickman-SteinN., Ganjei-AzarP., XuP., DoergeD.R., KrischerJ. (2011) Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Archives of Internal Medicine, 171, 1363–1369.
58.
DanielP., DarrenJ.P., WendyL., MarkS.W., ShrutiS., KatherinA.F., StefanieN.V. (2012) 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates Stimulator of Interferon Gene (STING)- dependent innate immune pathways and is regulated by mitochondrial membrane potential. Journal of Biological Chemistry, 287, 39776–39788.
59.
BuchananC.M., ShihJ.H., AstinJ.W., RewcastleG.W., FlanaganJ.U., CrosierP.S., ShepherdP.R. (2012) DMXAA (Vadimezan, ASA404) is a multikinase inhibitor targeting VEGFR2 in particular. Clinical Science (London), 122, 449–457.
60.
WenjunN., JiaJi, ZunyanD., AudreyP., AmyJ.J., SunjooA., KatherineL.F., ThomasS.L., JamesT.D., XiaobaiL., DavidJ., JohnC.B., WolfgangS., MichaelR.G., MitchA.P.A. (2010) Phelps. Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS ONE, 5, e13792.
Yi-PingZ., Xin-EnH., JieC., Yan-YanLu, Xue-YanW., JinL., XiaX., JinX., Li-HongY. (2012) Clinical Safety and Efficacy of Kanglaite(Coix Seed Oil) Injection Combined with Chemotherapy in Treating Patients with Gastric CancerAsian Pacific Journal of Cancer Preview, 13, 5319–5321.
LeeC.C., LinC.P., LeeY.L., WangG.C., ChengY.C., LiuH.E. (2010) Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Leukemia and Lymphoma, 51, 897–905.
65.
SimonM., FrankA., PierraR., SusanH., DavidB., MichaelM., ArunD. (2012) Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. Journal of Biosciences, 37, 73–84.
66.
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients with Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer.http://www.clinicaltrials.gov/ct2/show/NCT00091377.
67.
JuergenF., FoellD.M., CorinnaG., DieterK., MartinS. (2008) Staege Sensitivity of Hodgkin's Lymphoma Cell Lines to the Cell Cycle Inhibitor Roscovitine. Anti-cancer Research, 28, 887–894.
KimS., HwangB.Y., SuB.N., ChaiH., MiQ., KinghornA.D., WildR., SwansonS.M. (2007) Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anti-cancer Research, 27, 2175–2183.
PearsonL., MihaliT., MoffittM., KellmannR., NeilanB. (2010) On the chemistry, toxicology and genetics of the cyanobacterial toxins, microcystin, nodularin, saxitoxin and cylindrospermopsin. Marine Drugs, 8, 1650–1680.
74.
JensenP.R., WilliamsP.G., OhD.C., ZeiglerL., FenicalW. (2007) Species-specific secondary metabolite production in marine actinomycetes of the genus Salinispora. Applied Environmental Microbiology, 73, 1146–1152.
75.
ThornburgC.C., ZabriskieT.M., McPhailK.L. (2010) Deep-sea hydrothermal vents: potential hot spots for natural products discovery. Journal of Natural Products, 73, 489–499.
76.
FujiwaraS. (2002) Extremophiles: developments of their special functions and potential resources. Journal of Biosciences and Bioengineering, 94, 518–525.
77.
KroissJ., KaltenpothM., SchneiderB., SchwingerM.G., HertweckC., MaddulaR.K., StrohmE., SvatosA. (2010) Symbiotic Streptomycetes provide antibiotic combination prophylaxis for wasp offspring. Natural Chemical Biology, 6, 261–263.
78.
VézinaC., KudelskiA., SehgalS.N. (1975) “Rapamycin (AY-22,989), a new antifungal antibiotic”. Journal of Antibiotic, 28, 721–6.
79.
LihaoM., RoyceM., BenjaminH.B.K., MikaelE., NyS., CraigM.C. (1999) Epoxomicin, a potent and selectiveproteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proceedings of the National Academy of Science USA, 96, 10403–10408.
BigioniM., BenzoA., IrrissutoC., LopezG., CuratellaB., MaggiC.A., ManziniS., CreaA., CaroliS., CubaddaF., BinaschiM. (2008) Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft. Cancer Chemotherapy Pharmacology, 62, 621–629.
88.
BellarosaD., BinaschiM., MaggiC.A., GosoC. (2005) Sabarubicin- (MEN 10755) and paclitaxel show different kinetics in nuclear factor-kappaB (NF-kB) activation: effect of parthenolide on their cytotoxicity. Anti-cancer Research, 25, 2119–2128.
89.
MazziniS., ScaglioniL., AnimatiF., MondelliR. (2010) Interaction between double helix DNA fragments and the new antitumor agent sabarubicin Men10755. Bioorganic and Medicinal Chemistry, 18, 1497–1506.
90.
CaponigroF., WillemseP., SorioR., FloquetA., van BelleS., DemolJ., TambaroR., ComandiniA., CapriatiA., AdankS., WandersJ. (2005) A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Investigational New Drugs, 23, 85–89.
91.
CristinaG., MariaA.S., DarioB., MarinaC., AurelioM., LuigiQ., MauraF., MassimoB. (2006) Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines. Proceedings for American Association for Cancer Research, 47, Abstract #3845.
92.
FrancescoIzzo, ThomasJ.V., GennaroG.C., MarkR.M., JuanW.V., RenateH., CosmoD.G., MarcellaM., AnnaP., MariangelaM., CristinaD., FrancescoF. (2013) Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results. Journal. Clinical Oncology, 31, suppl; abstr e15061.
ParijatM., DipakD. (2011) Effect of DNA Groove Binder Distamycin A upon Chromatin Structure. PLoS ONE, 6, e26486.
99.
BrunoP., IolandaF., StefanoD.T., CarloA.M., LucianoM., EttoreN., AntonioR., ConcettaG. (2010) Selective Binding of Distamycin A Derivative to G-Quadruplex Structure [d(TGGGGT)]4.Journal of Nucleic Acids, Volume 2010 (2010), Article ID 247137, 7 pages.
100.
ModiS., StopeckA., LindenH., SolitD., ChandarlapatyS., RosenN., D'AndreaG., DicklerM., MoynahanM.E., SugarmanS., MaW., PatilS., NortonL., HannahA.L., HudisC. (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research, 17, 5132–5139.
101.
KatragaddaU., FanW., WangY., TengQ., TanC. (2013) Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS One, 8, e58619.
102.
PaceyS., WilsonR.H., WaltoM., EatockM.M., HardcastleA., ZetterlundA., ArkenauH.T., Moreno-FarreJ., BanerjiU., RoelsB., PeacheyH., AherneW., de BonoJ.S., RaynaudF., WorkmanP., JudsonI. (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clinical Cancer Research, 17, 1561–1570.
PortugalJ. (2003) Chartreusin, elsamicin A and related anticancer antibiotics. Current Medicinal Chemistry. Anti-cancer agents, 3, 411–420.
106.
LamksV., VeitchJ.A., ForenzaS., CombsC.M., ColsonL. (1989) Biosynthesis of elsamicin A, a novel antitumour antibiotic. Journal of Natural Products, 52, 1015–1021.
107.
AsaiG., YamamatoN., ToiM., ShinE., NishiyamaK., SekineT., NomuraY., TakashimaS., KimuraM., TominagaT. (2002) Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast. Cancer Chemotherapy and Pharmacology, 49, 468–472.
108.
OmuraS., IwaiY., HiranoA., NakagawaA., AwayaJ., TsuchiyaH., TakahashiY., MasumaR. (1977) A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. Journal of Antibiotics (Tokyo), 30, 275–282.
109.
TamaokiT., NomotH., TakahashiI., KatoY., MorimotoM., TomitaF. (1986) Staurosporine, a potent inhibitor of phospholipid /Ca++ dependent protein kinase. Biochemical and Biophysical Research Communication, 135, 397–402.
110.
YamadaS., HirotaK., ChidaK., KurokiT. (1988) Inhibition of phorbol ester-caused induction of ornithine decarboxylase and tumor promotion in mouse skin by staurosporine, a potent inhibitor of protein kinase C. Biochemical and Biophysical Research Communication, 157, 9–15
111.
PaulaC.J., DiegoV.W., ElthonG.F., RenataT., ManoelO De.M, Edilberto R daS., Tito M daC.L., NorbertoP.L., LeticiaV.C.L. (2012) Structure Elucidation and Anticancer Activity of 7-Oxostaurosporine Derivatives from the Brazilian Endemic Tunicate Eudistoma vannamei. Marine Drugs, 10, 1092–1102.
AdamD.C., CatherineD., AliceH.L., SebastienL., JoelM., RobertH., YanfengW. (2012) Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Cancer Chemotherapy and Pharmacology, 69, 1255–1263.
115.
StoneR.M., FischerT., PaquetteR., SchillerG., SchifferC.A., EhningerG., CortesJ., KantarjianH.M., DeAngeloD.J., Huntsman-LabedA., DutreixC., del CorralA., GilesF. (2012) Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia, 26, 2061–2068.
116.
FischerT., StoneR.M., DeangeloD.J., GalinskyI., EsteyE., LanzaC., FoxE., EhningerG., FeldmanE.J., SchillerG.J., KlimekV.M., NimerS.D., GillilandD.G., DutreixC., Huntsman-LabedA., VirkusJ. (2010) Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Journal of Clinical Oncology, 28, 4339–4345.
RogalskaA., MarczakA., GajekA., SzwedM., ŚliwińskaA., DrzewoskiJ., JóźwiakZ. (2013) Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicology In Vitro, 27, 239–249.
McMeekinS., PatelR., VerschraegenC., CelanoP., BurkeJ., PlaxeS., GhatageP., GiurescuM., StredderC., WangY., SchmelterT. (2012) Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Brazilian Journal of Cancer, 106, 70–76.
122.
RustinG., ReedN., JaysonG.C., LedermannJ.A., AdamsM., PerrenT., PooleC, LindM., PersicM., EssapenS., GoreM., CalvertH., StredderC., WagnerA., GiurescuM., KayeS. (2011) A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology, 22, 2411–2416.
123.
BeerT.M., SmithD.C., HussainA., AlonsoM., WangJ.M., GiurescuK.R., WangY. (2012) Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the department of defence prostate cancer clinical trials consortium. Brazilian Journal of Cancer, 107, 808–813.
RobertM.B., GregoryD.V. (2002) Epothilones: new tubulin polymerization agents in preclinical and clinical development. Drugs Future, 27, 1149–1163.
127.
ArunK.G., DavidD.A. (2012) Enantioselective Total Synthesis of Pladienolide B: A Potent Spliceosome Inhibitor. Organic Letters, 14, 4730–4733.
128.
MasaoIwata (2004) E7107, a new 7-urethane derivative of pladienolide D, displays curative effect against several human tumor xenografts. Proceedings of American Association for Cancer Research, 45. Abstract #2989
129.
A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours. Clinical Trials.gov Identifier: NCT00459823.
130.
FolcoE.G., CoilK.E., ReedR. (2011) The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes & Development, 25, 440–444.
RizzieriD.A., FeldmanE., DipersioJ.F., GabrailN., StockW., StrairR., RiveraV.M., AlbitarM., BedrosianC.L., GilesF.J. (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 14, 2756–2762.
133.
UsamaR.A., MatthiasS., EmanM.O., TanjaS., StephanieG., HelgaS., UteH. (2012) Antioxidant and Anti-Protease Activities of Diazepinomicin from the Sponge-Associated Mcromonospora Strain RV115. Marine Drugs, 10, 2208–2221.
134.
BoufaiedN., WiolandM.A., FalardeauP., GourdeauH. (2010) TLN-4601, a novel anticancer agent, inhibits Rassignaling post Rasprenylation and before MEK activationWioland MA, Falardeau P, Gourdeau H. Anti-cancer Drugs, 21, 543–552.
135.
CampbellP.M., BoufaiedN., FiordalisiJ.J., CoxA.D., FalardeauP., DerC.J., GourdeauH. (2010) TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. Journal of Molecular Signaling, 5, 18–28.
136.
MasonW.P., BelangerK., NicholasG., VallièresI., MathieuD., KavanP., DesjardinsA., OmuroA., ReymondD. (2012) A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. Journal of Neurooncology, 107, 343–349.
137.
RobertM.Q., ShanksM., RoniM.L., NicholasA.S., DanielH.K., XinyuL., EricJK A., RoniM.L., NicholasA.S., DanielH.K., XinyuL., EricJ.K. (2013) SerratiamarcescensPigPhomolog controls prodigiosin biosynthesis, swarming motility and haemolysis and is regulated by cAMP-CRP and HexS Shanks mail, Plos ONE, 8, e57634.
138.
BodeH.B., BetheB., HöfsR., ZeekA. (2002) Big effects from small changes: possible ways to explore nature's chemical diversity. Chemistry and Chemical Biology, 3, 619–627.
139.
ChinY.W., BalunasM.J., ChaiH.B. (2006) Drug discovery from natural sources. The AAPS Journal, 8, 239–253.
140.
DonadioS., MonicardiniP., AlduinaR., MazzaaP., ChiocchiniC., CavalettiL., SosioM., PugliaA.M. (2002) Microbial technologies for the discovery of novel bioactive metabolites. Journal of Biotechnology, 99, 187–198.
141.
GunatilakaA.A.L. (2006) Natural products from plant-associated microorganisms: Distribution, structural diversity, bioactivity, and implications of their occurrence. Journal of Natural Products, 69, 509–526.
142.
MitchellA.M., StrobelG.A., HessW.M., VargasP.N., EzraD. (2008) Muscodorcrispans, a novel endophyte from Anansananassoides in the BolivianAmazon, Fungal Diversity, 31, 37–43.
143.
KockJ.L.F., StraussT., PohlC.H., SmithD.P., BotesP.J., PretoriusE.E., TepenyT., SebolaiO., BothaA., NigamS. (2001) Bioprospecting for novel oxylipins in fungi: the presence of 3-hydroxy oxylipins in Pilobolus. Antonie van Leeuwenhoek, 80, 93–99.
144.
MisiekM., HoffmeisterD. (2007) Fungal genetics, genomics, and secondary metabolites in pharmaceutical sciences. Planta Medica, 73, 103–115.
145.
SchneiderP., MisiekM., HoffmeisterD. (2008) In vivo and in vitro production options for fungal secondary metabolites. Molecular Pharmacology, 5, 234–242.
146.
SelimK.A., El-BeihA.A., AbdEl-RahmanTM2, El-DiwanyA.I. (2012) Biology of endophytic fungi. Current Research in Environmental and Applied Mycology, 2, 84–97.
BirchA.J., HussainS.F. (1969) Studies in relation to biosynthesis. Part XXXVIII. A preliminary study of fumagillin. Journal of Chemical Society (C), 1473–1474.
149.
KrugerE.A., FiggW.D. (2000) TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opinion in Investigational Drugs, 9, 1383–1396.
150.
BernsenHjja, RijkenPfjw, PetersH., BakkerH., van der KogelA.J. (1998) The effect of the anti-angiogenic agent TNP-470 on tumor growth, vascular area, vascular density and tumor perfusion of two different subcutaneously implanted human glioma xenografts (E98 and E106) in nude mice. Journal of Neuro Oncolology, 38, 51–57.
SangJ.S., Hei-CheuJ., JoongB.A., SunY.R., JaeK.R., KyungS.P., Dal-HyunK., ChinK., HyunC.C. (2010) A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Investigational New Drugs, 28, 650–658.
153.
KimE.J., ShinW.H. (2005) General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biological and Pharmaceutical Bulletin, 28, 217–223.
154.
LeeH.S., ChoiW.K., SonH.J., LeeS.S., KimJ.K., AhnS.K., HongC.I., MinH.K., KimM., MyungS.W. (2004) Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. Archives of Pharmacal Research, 27, 265–272.
155.
ShinS.J., AhnJ.B., ParkK.S., LeeY.J., HongY.S., KimT.W., KimH.R., RhaS.Y., RohJ.K., KimD.H., KimC., ChungH.C. (2012) A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Investigational New Drugs, 30, 672–680.
156.
ThomasG., PaulA.K., KayC.P., LauraK.C., GaryM. (1996) MIsolation of IlludinS from the Mature Basidiocarp of Omphalotus Illudens, and Isolation of IlludinsS and M from the Fermentation Broth of Omphalotus Olearis. Natural Product Letters, 9, 87–95.
157.
HendrikG., IetidalE.M., AlexanderP., StefanK., HaraldG., GabrieleM.K. (2010) Fungal metabolites: structural diversity as incentivefor anticancer drug development. Phytochemistry Reviews, 9, 537–545.
158.
WangY., WiltshireT., SenftJ., WengerS.L., ReedE., WangW. (2006) Fanconianemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Molecular Cancer Therapeutics, 5, 3153–3161.
159.
ElinoarS. (2008) Irofulven – Halloween Trick or a Beacon of Light. Medicinal mushrooms, Volume 1: 1.
160.
RussellJ.S., JohnA.B., MarkS.S., DavidS.M, KrishnansuS.T., CarolynY.M., DavidW., McMeekinD.S., JacobR. (2010) A phase II evaluation of Irofulven (IND#55804, NSC#683863) as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group trial. International Journal of Gynecological Cancer, 20, 1137–1141.
161.
KanohK., KohnoS., AsariT., HaradaT., KatadaJ., MuramatsuM., KawashimaH., SekiyaH. (1997) Uno, I. (-)-Phenylahistin: a new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorganic and Medicinal Chemistry Letters, 7, 2847–2852.
162.
MillwardM., MainwaringP., MitaA., FedericoK., LloydG.K., ReddingerN., NawrockiS., MitaM. (2012) Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel Spear MAMain waring P. Investigational New Drugs, 30, 1065–73.
163.
BertelsenL.B., ShenY.Y., NielsenT., Stødkilde-JørgensenH., LloydG.K., SiemannD.W., HorsmanM.R. (2011) Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. International Journal of Radiation Biology, 87, 1126–1134.
164.
MitaM.M., SpearM.A., YeeL.K., MitaA.C., HeathE.I., PapadopoulosK.P., FedericoK.C., ReichS.D., RomeroO., MalburgL., PilatM., LloydG.K., NeuteboomS.T., CroppG., AshtonE., LoRussoP.M. (2010) Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clinical Cancer Research, 16, 5892–5899.
165.
MitaA.C., HeistR.S., ArenO., MainwaringP.N., BazhenovaL., GadgeelS.M., BlumR. H., PolikoffJ., BiswasJ., SpearM.A. (2010) Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 28, 15–16.
166.
BergmannW., FeeneyR.J. (1951) Contributions to the study of marine products. XXXII. The nucleosides of sponges. Journal of Organic Chemistry, 16, 981–987.
167.
BergmannW., BurkeD.C. (1955) Contributions to the study of marine products. XXXIX. The nucleosides of sponges. III. Spongothymadine and spongouridine. Journal of Organic Chemistry, 20, 1501–1507.
168.
BergmannW., StempienM.F. (1957) Contributions to the study of marine products. Journal of Organic Chemistry, 22, 1575–1577.
169.
SucklingC.J. (1991) Chemical approaches to the discovery of new drugs. Science Programing, 75, 323–59.
170.
JensenP.R., FenicalW. (2000) Marine microorganism and drug discovery: Current status and future potential. In: FusetaniN. (ed.) Drugs from the Sea.Karger, Basel, 6–29.
171.
NewmanD.J., CraggG.M. (2004) Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Current Medicinal Chemistry, 11, 1693–1713.
172.
NewmanD.J., CraggG.M. (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. Journal of Natural Products, 67, 1216–38.
173.
TarabolettiG., PoliM., DossiR. (2004) Antiangiogenic activity of aplidine, a new agent of marine origin. Brazilian Journal of Cancer, 90, 2418–2424.
174.
WangW.S., TzengC.H., ChiouT.J., LiuJ.H., HsiehR.K., YenC.C., ChenP.M. (1997) High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Japanese Journal of Clinical Oncology, 27, 154–157.
175.
MayerA.M.S., GlaserK.B., CuevasC., JacobsR.S., KemW., LittleR.D., McIntoshJ.M., NewmanD.J., PottsB.C., ShusterD.E. (2010) The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends in Pharmacological Science, 31, 255–265.
176.
AbrahamI., Sayed ElK., ChenZ.S., GuoH. (2012) Current status on marine products with reversal effect on cancer multidrug resistance. Marine Drugs, 10, 2312–2321.
ChristosV., AndresF.T. (2012) Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Therapeutics Advances in Hematology, 3, 209–225.
180.
BoopathyN.S., KathiresanK. (2010) Anticancer drugs from marine flora: an overview. Journal of Oncology, 214186, 1–18.
181.
LueschH., ChandaS.K., RayaR.M., DeJesusP.D., OrthA.P., WalkerJ.R., Izpisúa BelmonteJ.C., SchultzP.G. (2006) A functional genomics approach to the mode of action of apratoxin A. Nature Chemical Biology, 2, 158–567.
182.
RanaM., HendrikL. (2011) Marine natural products: new wave of drugs. Future Medicinal Chemistry, 3, 1475–1489.
183.
JiyongH., HendrikL. (2012) Largazole: From discovery to broad-spectrum therapy. Natural Product Reports, 29, 449–456.
184.
RinehartK., GloerJ.B., CookJ.C. (1981) Structures of didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. Journal of American Chemical Society, 103, 1857–1859.
185.
NuijenB., BoumaM., ManadaC., JimenoJ.M., SchellensJ.H.M., BultA., BeijnenJ.H. (2000) Pharmaceutical development of anticancer agents derived from marine sources. Anti-Cancer Drugs, 11, 793–811.
186.
PitotH.C., McElroyEajr, ReidJ.M. (1999) Phase I trial of dolastatin-10 (NSC 37612in patients with advanced solid tumors. Clinical Cancer Research, 5, 525–31.
187.
VaishampayanU., GlodeM., DuW., KraftA., HudesG., WrightJ., HussainM. (2000) Phase II Study of Dolastatin 10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clinical Cancer Research, 6, 4205–4208.
188.
HoffmanM., BlessingJ., LentzS. (2003) A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology, 89, 95–8.
189.
SimmonsT.L., EricA., KerryM., PatriciaF., WilliamH.G. (2005) Marine natural products as anticancer drugs. Molecular Cancer Therapeutics, 4, 333–342.
190.
KerbratP., DierasV., PavlidisN., RavaudA., WandersJ., FumoleauP. (2003) Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. European Journal of Cancer, 39, 317–320.
191.
MarksR., GrahamD., SloanJ (2003) A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. American Journal of Clinical Oncology, 26, 336–337.
192.
SmythJ., BoneterreM.E., SchellensJ., CalvertH., GreimG., WandersJ., HanauskeA. (2001) Activity of the dolastatin analogue, LU103793, in malignant melanoma. Annals of Oncology, 12, 509–511.
193.
LuC., LeeJ.J., KomakiR., HerbstR.S., FengL., EvansW.K., ChoyH., DesjardinsP., EsparazB.T., TruongM.T., SaxmanS., KelaghanJ., BleyerA., FischM.J. (2010) Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. Journal of National Cancer Institute, 102, 859–865.
194.
DumezH., GallH., CapdevilleR., DutreixC., van OosteromA.T., GiacconeG. (2007) A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anti-cancer Drugs, 18, 219–225.
195.
CernaianuG., FrankS., ErbstösserK., LeonhardtS., CrossM., McIvorZ., ScholzG., DansranjavinT., CelikI., TannapfelA., WittekindC., TroebsR.B., RotheK., BennekJ., HaussJ., WitzigmannH. (2006) TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model. International Journal of Colorectal Disease, 21, 143–154.
196.
PandaD., DeLucaK., WilliamsD., JordanM.A., WilsonL. (1998) Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proceedings of National Academy of Science U S A, 95, 9313–9318.
197.
LisaD., RobertL.F., TamaraN Do, GeoffreyP.D., DanielP.P. (2002) The novel anti-microtubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clinical Cancer Research, 8, 3922–3932.
198.
EdelmanM.J., GandaraD.R., HausnerP., IsraelV., ThorntonD., De SantoJ., DoyleL.A. (2003) Phase 2 study of cryptophysin 52 in patients previously treated with platinum based chemotherapy for advanced NSCLC. Lung cancer, 39, 197–199.
199.
StevensonJ.P., SunW., GallagherM., JohnsonR., VaughnD., SchuchterL., AlgazyK., HahnS., EnasN., EllisD., ThorntonD., O'DwyerP.J. (2002) Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 scheduleevery 21 days. Clinical Cancer Research, 8, 2524–2529.
200.
SessaC., Weigang-KohlerK., PaganiO., GreimG., MoraO., De PasT., BurgessM., WeimerI., JohnsonR. (2002) Phase I and pharmacological studies of the cryptophycinanalogue LY355703 administered on a single intermittent or weekly schedule. European Journal of Cancer, 38, 2388–2396.
201.
D'AgostinoG., CampoJ.D., MelladoB., IzquierdoM.A., MinarikT., CirriL., MariniL., Perez-GraciaJ.L., ScambiaG.A. (2006) A multicenter phase II study of the cryptophycinanalog LY355703 in patients with platinum-resistant ovarian cancer. International Journal of Gynaecological Cancer, 16, 71–76.
202.
LiangJ., MooreR.E., MaherE.D., MunroeJ.E., Al-awarR.S., HayD.A., VarieD.L., ZhangT.Y., AikinsJ.A., MastinelliM.J., ShihC., RayJ.E., GibsonL.L., VasudevanV., PalinL., WhiteK., KushnerJ., SimpsonC., PughS., CorbettT.H. (2005) Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors. Investigational New Drugs, 23, 213–224.
KortmanskyJ., SchwartzG.K. (2003) Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Investigation, 21, 924–936.
205.
Tourneau LeC., FaivreS., CiruelosE., DomínguezM.J., López-MartínJ.A., IzquierdoM.A., JimenoJ., RaymondE. (2010) Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. American Journal of Clinical Oncology, 33, 132–136.
206.
BaudinE., DrozJ.P., Paz-AresL., van OosteromA.T., Cullell-YoungM., SchlumbergerM. (2010) Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. American Journal of Clinical Oncology, 33, 83–8.
207.
Randomized, multicenter, open-label, phase III study of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. http://clinresearch.info/research/index/NCT01102426.
208.
VincentR., DoloresC., ChristopheF., EmanueleZ., ReyesA., JavierB., ChristianG., GillesS., AlessandroM.G., HenryG., CarmenK., ClaudiaC., SergioS., SoniaE., Bernardo deM., MartinC-Y, FrancoC. (2013) Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-hodgkin's lymphoma. Haematology, 98, 357–363.
FelingR.H., BuchananG.O., MincerT.J., KauffmanC.A., JensenP.R., FenicalW. (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angewandte Chemie International Edition, 42, 355–357.
211.
WilliamF., PaulR.J., MichaelA.P., KinS.L., KennethG.L., BarbaraC.P. (2009) Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorganic and Medicinal Chemistry, 17, 2175–2180.
212.
AmandaO., JeffreyW., BrettW., RamaR.M., VenkatR.M., KatherineM., Ta-Hsiang, MichaelA.P.G., KennethL., BarbaraC. P., SalvatoreJ.E., SaskiaT.C.N., BrunoH.H. (2011) Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs. Journal of Pharmacology and Experimental Therapeutics, 337, 479–486.
213.
TadeuszF.M., DoralynS.D., SarahL.L., JonelP.S. (2009) Drug development from marine natural products. Nature Reviews Drug Discovery, 8, 69–85.
YounesA., SuredaA., Ben-YehudaD., ZinzaniP.L., OngT.C., PrinceH.M. (2012) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. Journal of Clinical Oncology, 30, 2197–203.
218.
MascarenhasJ., LuM., LiT., PetersenB., HochmanT., NajfeldV., GoldbergJ.D., HoffmanR.A. (2013) phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Brazilian Journal of Haematology, 161, 68–75.
219.
FrinckeJ.M., FaulknerD.J. (1982) Antimicrobial metabolites of the sponge Reniera sp. Journal of American Chemical Society, 104, 265–269.
220.
DavidsonB.S., RenieramycinG. (1992) A new alkaloid from the sponge Xestospongia caycedoi. Tetrahedron Letters, 33, 3721–3724.
221.
FontanaA., CavaliereP., WahidullaS., NaikC.G., CiminoG. (2000) A new antitumourisoquinoline alkaloid from the marine nudibranch Jorunna funebris. Tetrahedron, 56, 7305–7308.
222.
CapdevilaJ., CliveS., CasadoE., MichieC., PieraA., SicartE. (2013) A phase I pharmacokinetic study of PM00104 (Zalypsis(®)) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. Cancer Chemotherapy Pharmacology, 71, 1247–1254.
223.
GonzálezS.M., ValenzuelaB., Pérez-RuixoC., FernándezT.C., Miguel-LilloB., Soto-MatosA., Pérez-RuixoJ. (2012) Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104. Journal of Clinical Pharmacokinetics, 51, 751–764.
224.
RinehartK., HoltT.G., FregeauN.L., StrohJ.G., KeiferP.A., SunF. (1990) Ecteinascidins 729, 743, 745, 759A, 759B and 770: potent antitumor agents from the Caribean tunicate Ecteinascidia turbinate. Journal of Organic Chemistry, 55, 4512–4515.
225.
ManzanaresI., CuevasC., Garcia-NietoR., MarcoE., GagoF. (2001) Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents. Currunt Medicinal Chemistry Anti-cancer Agents, 1, 257–276.
226.
LealJ.F.M., Martínez-DíezM., García-HernándezV., MoneoV., DomingoA., Bueren-CalabuigJ.A., NegriA., GagoF., Guillén-NavarroM.J., AvilésP., CuevasC., García-FernándezL.F., GalmariniC.M. (2010) PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Brazilian Journal of Pharmacology, 161, 1099–1110.
227.
A phase II clinical trial of PM01183 in BRCA 1/2-associated or unselected metastatic breast cancer. http//www.clinical trials gov NCT01525589.
228.
GalinaK., KarenT.D., MurrayJ.T., HongshengC., JunkeLiu, JoanneP.M., ShawnE.R.S., MarkR.S., HuY., BorisM.S., ChristinaJ.S., VeroniqueM., YeY., EdwardM.S., SilvioC., FrancisG.F., JamesJ.K., BruceA.L. (2009) Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Molecular Cancer Therapeutics, 8, 2852–2860.
229.
CaioM.R., SoleyB., JessicaM.I., LuisR., AureaM. F., AnnapoornaF., EricH. R., ElizabethA. P., AntoinetteR. T., AntonioL., NaseemZ. (2012) A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. Cancer, 118, 4262–4270.
230.
WetermanM.A., AjubiN., van DinterI.M., DegenW.G., van MuijenG.N., RuitterD.J. (1995) Bloemers, H.P.nmb, a novel gene, is expressed in lowmetastatic human melanoma cell lines and xenografts. International Journal of Cancer, 60, 73–81.
ZhouW., ZhuW-G. (2009) The changing face of HDAC inhibitor depsipeptide. Current Cancer Drug Targets, 9, 91–100.
237.
ZhuW.G., LakshmananR.R., BealM.D., OttersonG.A. (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase Inhibitors. Cancer Research, 61, 1327–1333.
238.
AdachiM., ZhangY., ZhaoX., MinamiT., KawamuraR., HinodaY., ImaiK. (2004) Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamicacid bis-hydroxamide with proteasome inhibitors PSI and PS–341 against gastrointestinal adenocarcinoma cells. Clinical Cancer Research, 10, 3853–3862.
239.
ChandraS., BandopadhyayR., KumarV., ChandraR. (2010) Acclimatization of tissue cultured plantlets: from laboratory to land. Biotechnology Letters, 32, 1191–1205.
240.
FirákováS., ŠturdíkováM., MúčkováM. (2007) Bioactive secondary metabolites produced by microorganisms associated with plants. Biologia, 62, 251–257.
241.
LimsuwanS., TripE.N., KouwencTrhm, PiersmacS., HiranratA., MahabusarakamW., VoravuthikunchaiS.P., Van DijlJ.M., KayserO. (2009) A new candidate as natural antibacterial drug from Rhodomyrtustomentosa. Phytomedicine, 16, 645–651.
242.
StierleA.A., StrobelG., StierleD.B. (1993) Taxol and taxane production by Taxomycesandreanae, an endophytic fungus of pacific yew. Science, 260, 214–216.
243.
GeJ., PingW., ZhouD. (2004) Characterization of a new species of taxol-producing fungus. Nature and Science, 2, 85–88.
244.
YuanJ., Jian-NanB., BingY., Xu-DongZ. (2006) Taxol-producing fungi: a new approach to industrial production of taxol. Chinese Journal of Biotechnology, 22, 1–6.
245.
KusariS., ZuhlkeS., SpitellerM. (2009) An endophytic fungus from Camptotheca acuminata that produces camptothecin and analogues. Journal of Natural Products, 72, 2–7.
246.
TouseefA., MusaratA., SharmaP.R., PuriS.C., HananM.Y., AreejM.A., QaziG.N. (2012) Effect of precursors feeding and media manipulation on production of novel anticancer pro-drug camptothecin from endophytic fungus. Brazilian Journal of Microbiology, 43, 1476–1489.
247.
KharwarR.N., VermaV.C., StrobelG., EzraD. (2008) The endophytic fungal complex of Catharanthus roseus (L.) G. Don. Current Science, 95, 228–233.
248.
EybergerA.L., DondapatiR., PorterJ.R. (2006) Endophyte fungal isolates from Podophyllum peltatum produces podophyllotoxin. Journal of Natural Products, 69, 1121–1124.
